• Ayala Pharmaceuticals Inc (NASDAQ: AYLA) initiated with Buy with a (around 120% upside) at Ladenburg Thalmann analyst price target.

• The analyst says the company has the most diversified gamma-secretase inhibitor play in the public markets.

• Demir sees near-to-medium term value play considering Ayala's "wide clinical pipeline that offers plenty of interesting /compelling optionality."

• In April, the first patient was dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for multiple myeloma.

• Ayala expects an initial interim data read-out from part A of desmoid tumor Phase 2/3 pivotal trial study and dose selection by mid-2022.

• Cash and cash equivalents of million are sufficient to provide a cash runway into 2023.

• Price Action: AYLA shares are up 17.3% at $12.43 during the market session on the last check Tuesday.

Latest Ratings for AYLA

View More Analyst Ratings for AYLA
View the Latest Analyst Ratings

See more from Benzinga

• Click here for options trades from Benzinga

• Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

• Genocea Biosciences Starts Dosing In Mid-Stage GEN-011 Study In Solid Tumors

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.